CITIUS ONCOLOGY INC
For the period ended Sep 30, 2024. Filed Dec 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Dec 27, 2024
CTOR$0.56+2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
| Preferred Stock · Common Stock · Additional Paid-In · Accumulated · Total Stockholders’ | |||||||
|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Capital | Deficit | Equity | |
| Balance, 30-Sep-22 | - | - | 67,500,000 | 6,750 | 41,693,250 | (5,432,599) | 36,267,401 |
| Stock-based compensation expense | - | - | - | - | 1,965,500 | - | 1,965,500 |
| Net loss | - | - | - | - | - | (12,697,241) | (12,697,241) |
| Balance, 30-Sep-23 | - | - | 67,500,000 | 6,750 | 43,658,750 | (18,129,840) | 25,535,660 |
| Capital contributions by parent | - | - | - | - | 37,008,905 | 37,008,905 | |
| Stock-based compensation expense | - | - | - | - | 7,498,817 | 7,498,817 | |
| Merger, net of transaction costs of $2,358,780 | - | - | 4,052,402 | 405 | (2,754,701) | (2,754,296) | |
| Net loss | (21,148,747) | (21,148,747) | |||||
| Balance, 30-Sep-24 | - | - | 71,552,402 | 7,155 | 85,411,771 | (39,278,587) | 46,140,339 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.